HOME
SEARCH
RSS FEED
SUBSCRIBE
Next-Generation Taxoids
Case ID:
8742
Web Published:
1/24/2020
Background
Paclitaxel and docetaxel have been extensively used in clinic for treatment of various cancers. However, their lack of tumor-specificity frequently results in an assortment of undesired side effects and exhibit little efficacy in treating melanoma, pancreatic, gastric, brain and renal cancers. These limitations are, at least in part, due to multi drug resistance (MDR) caused by over expression of ABC cassette efflux pumps and the beta III tubulin isoform.
Technology
Stony Brook University researchers have developed fluorine-containing asion in addition to being a inducer of apoptonext generation taxoid anticancer agents with superior pharmacological properties and improved potency against various classes of tumors, in particular drug resistant cancers and cancer stem cells. The potency of these next generation taxoids was evaluated against various drug sensitive and drug resistant cancer cell lines and patient derived cancer stem cells. The lead compound is a potent inhibitor of epithelial-mesenchymal transition(EMT), migration and invasion in breast cancer cells. Highly potent taxoids are also very important as the warheads of tumor targeting drug conjugates. Further Details - Zheng et al. Int J Oncolocy 2017 Mar; 50(3): 893-902
Advantages
- Novel next-generation taxoids - Superior potency - Block known metabolic pathways of toxoids - Strong EMT & cell migration/invasion inhibitor - Enhanced drug transportation and membrane permeability
Application
Oncology
Patent Status
Patent application submitted
Stage Of Development
PCT filed covering composition of matter and methods of use.
Licensing Potential
Licensing Status
Additional Info
https://stonybrook.technologypublisher.com/files/sites/vldclbxqketio4ilr6so_next-generation-taxoids-with-superior-anti-tumor-properties-header.png
Please note, header image is purely illustrative. Source: tineranttrader, Wikimedia Commons, CC0.
Patent Information:
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Category(s):
Campus > Stony Brook University
Technology Classifications > Therapeutics
Case ID: R8742
Bookmark this page
Download as PDF
For Information, Contact:
Sean Boykevisch
Director
State University of New York at Stony Brook
6316326952
sean.boykevisch@stonybrook.edu
Inventors:
Iwao Ojima
Changwei Wang
Xin Wang
Keywords:
Technologies